ArticleCommunications biology2026
Recurrent deletions and regulatory disruption of the Y chromosome in cancer.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Somatic loss of the Y chromosome (LOY) is the most frequent acquired genomic alteration in aging males and occurs across multiple cancer types. While common, its functional role in tumorigenesis is only beginning to emerge. Most studies treat LOY as a binary event, ignoring partial deletions that may selectively remove gene-rich euchromatic regions. To address this, we used high-coverage whole-genome sequencing, large-scale transcriptomics, and eQTL to map male cancer cell lines, eliminating confounding non-malignant cells. We reveal a region-specific LOY landscape with recurrent euchromatic deletions affecting protein-coding genes and non-coding elements. Losses were quantified using a new Y EroSion (YES) Score, which is associated with transcriptional differences and clinical outcome patterns suggestive of functional relevance. Retained Y-linked loci remain transcriptionally active, enriched for proliferation, immune signaling, and stress adaptation functions. These findings position LOY as a structured genomic event with regulatory and clinical implications, motivating validation in primary tumor cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.